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Introduction: Lymphatic permeation has been reported as a prog-
nostic factor for patients with resected non–small-cell lung cancer 
(NSCLC). Lymphatic canals are located in both intratumoral and 
extratumoral areas. Since 2001, we have prospectively evaluated 
lymphatic permeation based on its location. The purpose of this study 
was to determine the survival impact of extratumoral lymphatic per-
meation in patients with resected NSCLC by analyzing the  long-term 
follow-up data.
Methods: We reviewed 1069 consecutive patients with NSCLC who 
underwent complete resection between 2001 and 2006. Lymphatic 
permeation was classified as follows: ly0, absence of lymphatic per-
meation; ly1, intratumoral; and ly2, extratumoral.
Results: There were 845 patients (79%) with ly0, 134 (12%) with ly1, 
and 90 (9%) with ly2. Ly2 was more frequently observed in patients 
with advanced disease and intrapulmonary metastases than ly0–1. 
The 5-year overall survival (OS) rates of the ly0, ly1, and ly2 groups 
were 75%, 63%, and 34%, respectively. The OS rate was significantly 
worse in the ly2 group compared with OS rate in the ly0 (p < 0.01) 
and ly1 groups (p < 0.01). In multivariate analyses, ly2 proved to be 
an independent poor prognostic factor (hazard ratio, 1.73; p < 0.01). 
OS and recurrence-free survival of patients with T1 and T2 tumors 
with ly2 were not statistically different from that of the patients 
with T3 tumor (OS, p = 0.43 and p = 0.77; recurrence-free survival, 
p = 0.94 and p = 0.94, respectively).
Conclusions: The adverse prognostic impact of lymphatic permeation 
was remarkably different whether it is detected in intratumoral or extra-
tumoral lymphatic canals. We recommend that lymphatic permeation 
in resected NSCLC should be evaluated by considering its location.
Key Words: Non–small-cell lung cancer, Surgery, Lymphatic per-
meation, Prognostic factor.
(J Thorac Oncol. 2014;9: 337–344)
Lung cancer is one of the most prevalent and lethal cancers worldwide. Surgery is the most effective treatment modal-
ity for patients with localized non–small-cell lung cancer 
(NSCLC); however, many patients develop recurrence even 
after complete resection. Many studies have reported that 
clinicopathological factors are associated with the survival of 
patients who undergo surgical treatment for NSCLC.1–5 Among 
these factors, vessel involvement, that is, vascular invasion 
and lymphatic permeation, has been well investigated.3,6,7 
Some investigators have collectively studied vascular invasion 
and lymphatic permeation as microscopic vessel invasion.8 
However, others have reported that lymphatic permeation 
had a survival impact which is different from that of vascu-
lar invasion.9,10 The current Tumor–Node–Metastasis (TNM) 
classification of lung cancer describes vascular invasion and 
lymphatic permeation as optimal descriptors which deserve 
future consideration of incorporation into the staging system.11 
Lymphatic canals are distributed in intratumoral and extratu-
moral areas in resected lung cancer specimens. Lymphatic per-
meation may have a different impact on the outcome according 
to its location. Since 2001, we have been classifying lymphatic 
permeation in patients with resected NSCLC into the follow-
ing three categories: absence of lymphatic permeation (ly0), 
intratumoral lymphatic permeation (ly1), and extratumoral 
lymphatic permeation (ly2). We had previously reported that 
patients with ly2 NSCLC significantly developed more recur-
rence than patients with ly1 tumor.12 However, the follow-up 
duration was relatively short, and the 5-year survival data were 
not available at that time. We continued to classify lymphatic 
permeation, and thus the longer-term follow-up data are now 
available. In this study, we report the 5-year overall survival 
(OS) data for patients with surgically resected ly2 NSCLC and 
the clinical significance of these findings.
PATIENTS AND METHODS
Patient Selection
Between August 2001 and December 2006, a total 
of 1069 consecutive patients underwent surgical resection 
for NSCLC by segmentectomy or greater lung resection 
with lymph node dissection in our institution and were ret-
rospectively enrolled in this study. This study was approved 
by the institutional review board in June 2012, and the need 
to obtain written informed consent was waived. Patients 
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who underwent preoperative chemotherapy, radiotherapy, or 
incomplete resection were excluded. All patients underwent 
preoperative evaluation, including physical examination, 
chest radiography, and chest and upper abdomen computed 
tomography (CT) scan. Magnetic resonance imaging of the 
brain, bone scintigraphy, and positron emission tomography 
were performed for patients who were suspected to have stage 
IB or more advanced disease on chest CT scans.
Histopathological Examination
Surgical specimens were immediately fixed in 10% for-
malin, and then cut horizontally at approximately 5-mm inter-
vals. As our routine process, we have created  paraffin-embedded 
sections of all cut surfaces containing the main tumor, irre-
spective of tumor location and its size. The serial 4-μm sec-
tions were stained with hematoxylin and eosin (HE) for routine 
histopathological workup. Histological typing of the primary 
tumor was performed in accordance with the World Health 
Organization classification.13 The pathological stage was deter-
mined on the basis of the 7th TNM classification of the Union 
for International Cancer Control. Victoria blue van Gieson 
staining to visualize elastic fibers was also routinely performed 
for all sections containing tumor cells to evaluate vascular inva-
sion, lymphatic permeation, and pleural invasion. Lymphatic 
permeation was suspected when floating tumor cells were iden-
tified in vessels with no supporting smooth muscles or when 
elastic fibers were identified.12,14,15 If lymphatic permeation was 
suspected in the HE sections, we also performed immunohis-
tochemical staining with  anti-D2-40 antibody to confirm the 
visualization of the lymphatic vessels (Fig. 1). We classified 
lymphatic permeation into the following three categories: ly0, 
absence of lymphatic permeation; ly1, presence of intratumoral 
lymphatic permeation (Fig. 1A and B); and ly2, presence of 
extratumoral lymphatic permeation (Fig. 1C and D). Ly2 were 
frequently identified around the subpleural spaces near the main 
tumor or bronchovascular bundles connecting the main tumor 
to hilum. Tumors with both ly1 and ly2 were classified as ly2. 
The lymphatic permeation status was prospectively evaluated 
by more than two pathologists and reviewed for the current 
study by one of the authors (G.I.).
Follow-Up and Evaluation of 
Recurrence and Survival
After the surgery, patients were followed-up at our outpa-
tient clinic. Patients were evaluated every 3 to 6 months during 
the first 2 years after surgery and every 6 to 12 months thereafter. 
The follow-up evaluation included physical examination, chest 
radiography, and blood examination, including tumor markers. 
Whenever any symptoms or signs of recurrence were detected, 
further evaluations were performed, including CT scans of the 
chest and abdomen, brain magnetic resonance imaging, and 
bone scintigraphy. Integrated positron emission tomography and 
CT scans were also performed for selected patients. Treatment 
after recurrence was determined by a board comprising thoracic 
surgeons, oncologists, and radiologists. The date of recurrence 
was defined as the date of histological proof or, in cases diag-
nosed on the basis of clinicoradiological findings, as the date of 
identification by a physician. Recurrences were categorized into 
locoregional recurrence and distant metastasis. Locoregional 
recurrence included recurrence in the bronchial stump, chest 
wall, residual lung field, chest cavity, and lymph nodes in the 
hilar, mediastinal, and cervical areas. Distant metastasis was 
defined as metastasis to extrathoracic organs, including the 
brain, bone, liver, adrenal gland, and others. Patients with both 
locoregional recurrence and distant metastases were classified 
as having distant metastases.
FIGURE 1.  Microscopic findings of 
intratumoral (A and B) and extratumoral 
(C and D) lymphatic permeation. A, 
Intratumoral lymphatic permeation is 
indicated by arrows (HE stain, original 
magnification ×100). B, Intratumoral 
lymphatic permeation detected by anti-
D2-40 immunostaining of lymphatic 
vessels (×100). Extratumoral lymphatic 
permeation by HE stain (C) (×100) and 
anti-D2-40 immunostaining (D) (×100). 
HE, hematoxylin and eosin.
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OS was defined as the interval in months between the 
date of surgical intervention and that of death due to any cause 
or the last follow-up. Observations were censored at the last 
follow-up when the patient was alive or was lost to  follow-up. 
The length of the recurrence-free period was calculated in 
months from the date of resection to that of the first recur-
rence or last follow-up.
Statistical Analysis
In this study, we compared the clinicopathological fac-
tors according to the lymphatic permeation status (ly0, ly1, 
and ly2). The relationship between ly status and the recurrence 
pattern was also evaluated. The prognostic impact of ly2 status 
was also evaluated in relation to other clinical and pathologi-
cal factors by univariate analyses. The significant factors in 
univariate analysis were then enrolled in multivariate analy-
sis. Relationship between pathological T factor and ly2 status 
was also evaluated as optional analysis. Fisher’s exact test or 
Pearson’s χ2 test were used to determine significant differences 
in patient characteristics between the two groups. For univari-
ate analyses, the Kaplan–Meier method was used to estimate 
all cumulative survival rates, and the log-rank test was used to 
calculate differences in variables. Cox proportional hazards 
regression models were used to perform multivariate analysis. 
Statistical analysis was performed using SPSS statistical soft-
ware (Dr. SPSS II for Windows, standard version 11.0; SPSS 
Inc., Chicago, IL).
RESULTS
Clinicopathological Characteristics 
of All Patients
Table 1 shows the clinicopathological characteristics 
of all 1069 patients. The median age was 65 years (range, 
20–90), and 672 patients (63%) were men. The median tumor 
size was 2.8 cm (range, 0.4–47). Pathological stage was I in 
714 patients (67%), II in 192 patients (18%), and III in 163 
patients (15%), respectively. Adenocarcinoma was the most 
common histological type (741; 69%), followed by squa-
mous cell carcinoma (243; 23%). Lymphatic permeation was 
detected in 224 patients (21%), whereas pleural invasion and 
vascular invasion were observed in 333 patients (31%) and 
487 patients (46%), respectively. The number of patients who 
received adjuvant chemotherapy was 18 (3%) in stage I, 14 
(7%) in stage II, and 17 (10%) in stage III, respectively.
Clinicopathological Characteristics According 
to Lymphatic Permeation Status
Table 2 shows the relationships between clinicopatho-
logical variables and the lymphatic permeation status. The 
number of patients classified as ly0, ly1, and ly2 were 845 
(79%), 134 (12%), and 90 (9%), respectively. The clinical 
factors, such as sex, age, and smoking history, were not sig-
nificantly different among each ly group. The surgical proce-
dures were 16 segmentectomies (ly0: 15, ly1: 0, and ly2: 1), 
1005 lobectomies (ly0: 805, ly1: 125, and ly2: 75), and 48 
pneumonectomies (ly0: 25, ly1: 9, and ly2: 14), respectively. 
In ly2 patients, there were significantly more patients having 
advanced nodal disease (pN1–2; 77% versus 46%; p < 0.01), 
advanced pathological stage (stage II to III; 81% versus 57%; 
p < 0.01), and tumors with intrapulmonary metastases (15% 
versus 5%; p = 0.02) when compared with ly1 patients. Ly0, 
ly1, and ly2 were observed in 588 (79%), 87 (12%), and 66 
(9%) patients with adenocarcinoma, respectively, whereas 
ly0, ly1, and ly2 were observed in 195 (80%), 31 (13%), and 
17 (7%) patients with squamous cell carcinoma, respectively. 
There was no significant difference in the distribution of the 
lymphatic permeation status between patients with adenocar-
cinoma and those with squamous cell carcinoma.
Survivals
The median follow-up duration was 85 months (range, 
1–124 months). During the study period, a total of 401 patients 
TABLE 1.  Clinicopathological Characteristics of All Patients
Characteristics
No. of Patients (%)
n = 1069
Median age (yr)
  Range 65 (20–90)
Sex
  Men 672 (63)
  Women 397 (37)
Smoking (pack-years)
  ≥40 417 (39)
  <40 652 (61)
CEA (ng/ml)
  >5 386 (36)
  ≤5 683 (64)
Median tumor size (cm)
  Range 2.8 (0.4–47)
pStage
  I 714 (67)
  II 192 (18)
  III 163 (15)
Histological type
  Adenocarcinoma 741 (69)
  Squamous cell carcinoma 243 (23)
  Large cell carcinoma 53 (5)
  Others 32 (3)
Pleural invasion
  Positive 333 (31)
  Negative 736 (69)
Vascular invasion
  Positive 487 (46)
  Negative 582 (54)
Lymphatic permeation
  Positive (ly1 and ly2) 224 (21)
  Negative (ly0) 845 (79)
Intrapulmonary metastasis
  Positive 36 (3)
  Negative 1033 (97)
CEA, serum carcinoembryonic antigen level (preoperative).
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died, that is, 269 patients (32%) with ly0, 67 (50%) with ly1, 
and 65 (71%) with ly2. Cancer recurrences were detected in 349 
patients, that is, 220 (26%) with ly0, 64 (48%) with ly1, and 65 
(71%) with ly2. Table 3 shows recurrence patterns according to 
the lymphatic permeation status. There were 160 locoregional 
recurrences and 189 distant metastases. Pleural dissemination 
was more frequent in the ly2 group compared with pleural dis-
semination in the ly0–1 group (ly0–1, 9%; ly2, 20%; p = 0.05).
Figure 2 shows the OS curves according to the lym-
phatic permeation status. The 5-year OS rates for ly0, ly1, 
and ly2 groups were 75%, 63%, and 34%, respectively. The 
survival curve of the ly2 group was significantly inferior 
to not only that of the ly0 group (p < 0.01) but also that of 
ly1 group (p < 0.01). Recurrence-free survival (RFS) and 
 cancer-specific survival in ly2 group were also poorer than 
those in ly0 or ly1 group (data shown in Supplemental Figures 
TABLE 2.  Clinicopathological Characteristics According to Lymphatic Permeation
ly0 (%)
n = 845
ly1 (%)
n = 134
ly2 (%)
n = 90
p
ly0 vs. 1–2
p
ly0–1 vs. 2
Sex
  Men 522 (62) 87 (65) 63 (69) 0.22 0.57
Age (yr)
  Median (range) 67 (20–90) 66 (22–85) 66 (41–83) 0.56 0.92
Smoking
  ≥40 p-y 333 (40) 49 (37) 35 (38) 0.54 1.00
FEV1 (liter)
  Median (range) 2.2 (0.6–4.6) 2.2 (0.8–3.7) 2.2 (1.2–3.6) 0.78 0.85
CEA (ng/ml)
  >5 288 (34) 58 (43) 40 (44) <0.01 0.89
Procedure
  Segment 15 (2) 0 1 (1)
  Lobe 805 (95) 125 (93) 75 (83) <0.01 <0.01
  Pneumo 25 (3) 9 (7) 14 (16)
Sizea (cm)
  Median (range) 2.7 (0.4–12) 3.5 (1.2–47) 3.4 (1.0–9.0) <0.01 0.34
pT status
  pT1 488 (58) 52 (39) 30 (33) <0.01b 0.31b
  pT2 285 (34) 60 (45) 37 (42)
  pT3/4 72 (8) 22 (16) 23 (25)
pN status
  pN0 714 (84) 72 (54) 21 (23) <0.01c <0.01c
  pN1 84 (10) 36 (27) 29 (32)
  pN2 47 (6) 26 (19) 40 (45)
pStage
  I 639 (76) 58 (43) 17 (18) <0.01d <0.01d
  II 126 (15) 40 (30) 26 (29)
  III 80 (9) 36 (27) 47 (52)
Histology
  Ad 588 (69) 87 (65) 66 (71) 0.63 0.39
  Sq 195 (23) 31 (23) 17 (18) 0.59 0.41
pl
  Present 221 (26) 67 (50) 45 (50) <0.01 1.00
pm
  Present 15 (2) 7 (5) 14 (15) <0.01 0.02
V
  Present 320 (38) 95 (71) 72 (80) <0.01 0.16
aSize; median tumor size (range).
bT1 vs. T2–4.
cN0 vs. N1–2.
dI vs. II to III.
p-y, pack-years; FEV, forced expiratory volume; CEA, serum carcinoembryonic antigen level (preoperative); Ad, adenocarcinoma; Sq, squamous cell carcinoma; pl, pleural 
invasion; pm, intrapulmonary metastasis; v, vascular invasion.
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1 and 2, Supplemental Digital Content 1 [http://links.lww.
com/JTO/A505] and Supplemental Digital Content 2 [http://
links.lww.com/JTO/A506]). When the OS was analyzed by 
pStages (pStage I and II to III), similar results were obtained 
to the entire cohort. In pStage I, the 5-year OS rates of ly0, 
ly1, and ly2 groups were 83%, 79%, and 47%, respectively 
(Fig. 3). The OS of the ly2 group was significantly inferior 
compared with that of the ly0 (p < 0.01) and ly1 groups 
(p = 0.05). In pStage II to III, the 5-year OS rates of ly0, 
ly1, and ly2 groups were 47%, 50%, and 25%, respectively. 
Ly2 was still a significant prognostic factor among the 
patients with pStage II to III (Fig. 4). Ly2 status also showed 
significant poor OS than ly0 or ly1 irrespective of pathological 
nodal (pN) status (data shown in Supplemental Figures 4–6, 
Supplemental Digital Content 3 [http://links.lww.com/JTO/
A507], Supplemental Digital Content 4 [http://links.lww.com/
JTO/A508], and Supplemental Digital Content 5 [http://links.
lww.com/JTO/A509]).
Table 4 shows the results of the univariate analyses of 
lymphatic permeation and other conventional clinicopatholog-
ical variables for prognostic factors. All variables were signifi-
cantly correlated with OS. Multivariate analyses revealed that 
age (≥70 years), pT status (pT2–4), pN status (pN1–2), pleu-
ral invasion (positive), intrapulmonary metastasis (positive), 
TABLE 3.  Recurrence Pattern According to the Lymphatic Permeation Status
No. of Recurrent pts. (%)
Total
n = 349
ly0
n = 220
ly1
n = 64
ly2
n = 65
p
ly0–1 vs. 2
Locoregional 160 (46) 100 (45) 31 (48) 29 (45) 0.58
  Local 8 (2) 6 (3) 1 (2) 1 (2) 1.0
  PMa 103 (30) 72 (33) 17 (27) 14 (22) 0.13
  Dissemination 39 (11) 17 (8) 10 (16) 12 (18) 0.05
  Lymph nodesb 61 (17) 33 (15) 15 (23) 13 (20) 0.59
Distant metastasesc 189 (54) 120 (55) 33 (52) 36 (55) 0.89
  Brain 90 (26) 51 (23) 17 (27) 22 (34) 0.12
  Bone 67 (19) 45 (20) 12 (19) 10 (15) 0.48
  Liver 39 (11) 24 (11) 7 (11) 8 (12) 0.83
  Adrenal gland 14 (4) 6 (3) 3 (5) 5 (8) 0.15
  Others 32 (9) 23 (10) 5 (8) 4 (6) 0.48
aPM means intrapulmonary metastasis.
bLymph node metastasis as locoregional recurrence includes metastasis in the hilar, mediastinal, and cervical lymph nodes.
cRecurrences in both locoregional and distant sites are included in the distant metastases.
FIGURE 2.  OS curves of patients with completely resected 
non–small-cell lung cancer according to the lymphatic 
permeation status (ly0, ly1, and ly2). The OS curve of the ly2 
group is significantly inferior compared with that of the ly0 
and ly1 groups. MST, median survival time; NR, not reached; 
OS, overall survival.
FIGURE 3.  OS curves of the patients with pStage I non–
small-cell lung cancer according to the lymphatic permeation 
status (ly0, ly1, and ly2). The OS curve of the ly2 group is 
significantly inferior compared with that of the ly0 and ly1 
groups. MST, median survival time; NR, not reached; OS, 
overall survival.
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vascular invasion (positive), and ly2 (positive) were indepen-
dent poor prognostic factors (Table 5). When the presence 
of lymphatic permeation (ly0 versus ly1–2) was enrolled in 
multivariate analyses instead of the presence of extratumoral 
lymphatic permeation (ly0–1 versus ly2), it did not reach sta-
tistical significance (p = 0.07; hazard ratio, 1.27; 95% confi-
dence intervals, 0.98–1.64).
Relationship between pT Factor and 
Extratumoral Lymphatic Permeation
Ly status is the information obtained from tumor (T) 
itself. Therefore, we also analyzed the relationship between 
pT factor and ly2. T1 and T2 tumors were classified into four 
groups according to the presence or absence of ly2, that is, 
T1 without ly2 (T1 − ly2), T1 with ly2 (T1 + ly2), T2 without 
ly2 (T2 − ly2), and T2 with ly2 (T2 + ly2). The RFS curve 
of each group was compared with each other and that of T3 
tumor. The 5-year RFS rates and median survival time of T1 
− ly2, T1 + ly2, T2 − ly2, T2 + ly2, and T3 populations were 
77% (not reached), 22% (22 months), 52% (66 months), 28% 
(17 months), and 30% (19 months), respectively (Fig. 5). 
Significant differences were observed between the T1 − ly2 
and T1 + ly2 groups (p < 0.01) and between the T2 − ly2 and 
T2 + ly2 groups (p < 0.01). Patients with T1 and T2 with ly2 
had poor outcomes, which were not statistically different from 
those with T3 tumors (p = 0.94 for both comparison). When 
only node-negative patients were analyzed, there were 488 T1 
− ly2, eight T1 + ly2, 249 T2−ly2, 11 T2 + ly2, and 51 T3 
patients. The number of ly2-positive patients was small (n = 19), 
but four of eight T1 + ly2 patients and five of 11 T2 + ly2 
patients developed relapse. As for the OS curves, the 5-year 
OS rates and median survival time of T1 − ly2, T1 + ly2, 
T2 − ly2, T2 + ly2, and T3 were 85% (not reached), 40% 
(55 months), 63% (93 months), 42% (53 months), and 37% 
(36 months), respectively (Supplemental Figure 3, Supplemental 
Digital Content 6, http://links.lww.com/JTO/A510). The same 
survival differences were observed between each group as 
shown in RFS analysis.
DISCUSSION
The present study retrospectively evaluated the prog-
nostic impact of extratumoral lymphatic permeation (ly2) in 
patients with completely resected NSCLC on the basis of our 
long-term follow-up data. We previously reported that ly2 was 
a useful prognostic marker,12 but this study could describe 
only RFS because of short follow-up period and small num-
ber of patients. The present study with enough long follow-up 
TABLE 4.  Univariate Analysis of Clinicopathological Factors 
Associated with Overall Survival
Variables
Five-year OS*  
Rate (%) p
Age (yr)
  <70 75 <0.01
  ≥70 63
Sex
  Women 81 <0.01
  Men 63
CEA (ng/ml)
  ≤5 76 <0.01
  >5 59
Smoking (pack-years)
  <40 76 <0.01
  ≥40 60
pT status
  pT1 83 <0.01
  pT2–4 55
pN status
  pN0 78 <0.01
  pN1–2 45
Pleural invasion
  Absent 79 <0.01
  Present 50
Intrapulmonary metastasis
  Absent 71 <0.01
  Present 28
Vascular invasion
  Absent 84 <0.01
  Present 53
Lymphatic permeation
  Absent (ly0) 75 <0.01
  Present (ly1–2) 51
Extratumoral lymphatic permeation
  Absent (ly0–1) 73 <0.01
  Present (ly2) 34
OS, overall survival; CEA, serum carcinoembryonic antigen level (preoperative).
FIGURE 4.  OS curves of the patients with pStage II and 
III non–small-cell lung cancer according to the lymphatic 
permeation status (ly0, ly1, and ly2). The OS curve of the 
ly2 group is significantly inferior compared with that of the 
ly0 and ly1 groups. MST, median survival time; OS, overall 
survival.
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period and large cohorts could evaluate OS. This mature sur-
vival data confirmed that patients with ly2 had significantly 
worse OS rates than not only those with ly0 but also those 
with ly1. Multivariate analysis also demonstrated that ly2 was 
an independent unfavorable prognostic factor associated with 
OS, which was as significant as advanced pT and pN status, 
pleural invasion, and intrapulmonary metastases. However, 
the presence of lymphatic permeation regardless of its extent 
(ly1–2) was not a statistically significant prognostic factor 
(p = 0.07). These results indicate that the presence of extratu-
moral lymphatic permeation (i.e., ly2) has a stronger prognos-
tic impact than that of intratumoral lymphatic permeation in 
general (i.e., ly1–2). Tumors classified as ly2 have additional 
cancer cells in the lymphatic vessels outside the main tumor. 
Therefore, ly2 tumors should have more chance to metastasize 
to lymph nodes and distant organs via lymphatic flow com-
pared with ly0 or ly1 tumors. In our cohort, ly2 group had 
more tumors with node involvement (77%) and recurrences 
(71%) than ly0 group (node involvement, 16%; recurrence, 
26%) or ly1 group (46% and 48%, respectively). Our results 
suggested that ly2 status had remarkable negative prognostic 
impact and should be included in the staging system.
Ly status is the information obtained from tumor (T) 
itself but not nodal (N) or metastatic (M) status. Therefore, 
the survival impact of ly2 status was analyzed by incorpo-
rating with the T classification of the TNM staging system. 
There were no statistically significant differences in OS and 
RFS between the T1/T2 tumors with ly2 and T3. Even in the 
small number of pN0 population, almost half the patients 
with ly2 tumor (4 of 8 T1 + ly2 patients and 5 of 11 T2 + 
ly2 patients) developed relapse. This analysis was exploratory 
because there might be other confounding clinicopathologi-
cal variables, such as pN status for analyzing the association 
between ly2 and pT factor. Actually, ly2 status was strongly 
related with pN status. But ly2 was found to be a significant 
poor prognostic indicator irrespective of pN status, as shown 
in Supplemental figures. Although our proposal is not com-
plete, these results implied that patients with ly2-positive T1–
2 diseases had extremely poor prognoses comparable with T3 
tumors. Currently, T1-2N0 disease is not globally indicated 
for adjuvant chemotherapy using cytotoxic agents. T1–2 N0 + 
ly2 disease may be upstaged to T3 and also be candidate for 
adjuvant chemotherapy.
Intrapulmonary metastases significantly occurred more 
frequently in ly2 tumors compared with that in ly0 or ly1 
tumors (ly2, 15%; ly1, 5%; ly0, 2%). Aokage et al.16 analyzed 
resected NSCLC with pulmonary metastases and revealed 
that some pulmonary metastases may be the result of lym-
phatic tumor spread. They hypothesized that tumor cells in the 
lymphatic vessels in bronchovascular bundles transmigrate to 
TABLE 5.  Multivariate Analysis of Clinicopathological 
Factors Associated with Overall Survival
Variables Hazard Ratio (95% CI) p
Age, yr
  <70 1.00 <0.01
  ≥70 1.52 (1.24–1.86)
Sex
  Women 1.00 0.26
  Men 1.16 (0.89–1.52)
CEA (ng/ml)
  ≤5 1.00 0.17
  >5 1.15 (0.94–1.41)
Smoking (pack-years)
  <40 1.00 0.25
  ≥40 1.15 (0.91–1.46)
pT status
  pT1 1.00 0.01
  pT2–4 1.37 (1.07–1.75)
pN status
  pN0 1.00 <0.01
  pN1–2 1.63 (1.30–2.04)
Pleural invasion
  Absent 1.00 <0.01
  Present 1.62 (1.29–2.02)
Intrapulmonary metastasis
  Absent 1.00 <0.01
  Present 2.61 (1.69–4.02)
Vascular invasion
  Absent 1.00 <0.01
  Present 1.70 (1.32–2.20)
Extratumoral lymphatic permeation
  Absent (ly0–1) 1.00 <0.01
  Present (ly2) 1.73 (1.31–2.30)
CEA, serum carcinoembryonic antigen level (preoperative); CI, confidence interval.
FIGURE 5.  RFS curves of the patients with non–small-cell 
lung cancer according to the T classification and extratumoral 
lymphatic permeation (ly2) status. The RFS curves of the T1 
+ ly2, T2 + ly2, and T3 populations are considerably similar 
to one another. MST, median survival time; NR, not reached; 
RFS, recurrence-free survival.
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the lung parenchyma and develop intrapulmonary metastases. 
The high frequency of intrapulmonary metastases in the ly2 
population in our study may be explained by this hypothesis.
Our results showed that lymphatic permeation was found 
in 20% (224 of 1095) of patients. But reported frequency of 
lymphatic permeation in NSCLC was ranged from 15% to 
40%.6,17–20 This discrepancy may be explained by the diffi-
culty in diagnosing lymphatic permeation. Lymphatic vessels 
lack elastic fibers in their walls, so it is basically hard to iden-
tify them by commonly used HE and elastic stains. In addi-
tion, when we found tumor cell clusters in elastic  fiber-absent 
canals, it was also difficult to distinguish lymphatic permeation 
from retraction artifacts caused by tissue processing. These 
difficulties might cause a scattering frequency of lymphatic 
permeation. Recently, anti-D2-40 immunohistochemical stain-
ing was introduced to help identify lymphatic vessels.12,14,15,21 
Lymphatic vessels are better visualized with this staining, as 
shown in Figure 1, which enables researchers to more precisely 
evaluate the presence of lymphatic permeation than without 
it. But it is not realistic to perform anti-D2-40 staining for all 
resected specimens because of its cost. Fortunately, extratu-
moral lymphatic permeation (i.e., ly2) seems to be more easily 
identified on routine HE staining compared with intratumoral 
lymphatic permeation (i.e., ly1) because retraction artifacts are 
much less frequent in the extratumoral areas. D2-40 immu-
nohistochemical staining may be required only for indistinct 
cases, particularly in the intratumoral areas.
A limitation of the present study was the type of the 
analysis. As described, we prospectively observed and clas-
sified the lymphatic permeation status by differentiating ly2 
and ly1 since 2001, but the analysis itself was retrospective in 
nature. In addition, this study was based on a  single-institution 
experience including mostly monoethnic patients. Further 
prospective, large-sized studies are required to confirm our 
findings. Standard diagnostic methodology should also be 
established to overcome difficulties in identifying lymphatic 
permeation.
In conclusion, extratumoral lymphatic permeation (i.e., 
ly2) was found to be an independent prognostic factor for 
patients with completely resected NSCLC. In this study, ly2 
had a stronger unfavorable impact on survival than intratu-
moral lymphatic permeation (i.e., ly1). We recommend a sep-
arate evaluation and classification of lymphatic permeation 
inside and outside the tumors. Further studies are warranted 
to discuss how to use prognostic impact of ly2 status in the 
TNM staging system.
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